{"id":"NCT03962101","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake","officialTitle":"A Multicenter, Open-label, Uncontrolled Clinical Trial to Confirm the Tolerability of OPC-61815 in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-17","primaryCompletion":"2020-06-30","completion":"2020-06-30","firstPosted":"2019-05-23","resultsPosted":"2021-09-05","lastUpdate":"2021-09-05"},"enrollment":45,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Congestive Heart Failure"],"interventions":[{"type":"DRUG","name":"OPC-61815 injection","otherNames":[]}],"arms":[{"label":"OPC-61815 injection","type":"EXPERIMENTAL"}],"summary":"To confirm the tolerability of intravenous administration of OPC-61815 at 8 or 16 mg once daily for a maximum of 5 days to CHF patients with volume overload despite having received diuretics (injection) other than vasopressin antagonists and who have difficulty with or are incapable of oral intake.","primaryOutcome":{"measure":"Percentage of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs","timeFrame":"From the start of IMP administration (Day 1) up to 15 days","effectByArm":[{"arm":"OPC-61815 Injection","deltaMin":77.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":38},"commonTop":["Constipation","Hepatic function abnormal","Urinary tract infection","Hypokalaemia","Insomnia"]}}